{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:40:12Z","timestamp":1765888812316,"version":"3.48.0"},"reference-count":34,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"unspecified","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014421","name":"EA Pharma Co., Ltd.","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014421","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Mochida Pharmaceutical Co., Ltd.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,11,26]]},"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Chronic constipation worsens the quality of life (QOL) of patients with Parkinson\u2019s disease (PD). Elobixibat, an ileal bile acid transporter inhibitor, is a useful laxative, but its effect on chronic constipation in patients with PD remains unclear. Therefore, we designed a placebo-controlled, randomised, double-blind study to investigate the efficacy and safety of elobixibat in patients with PD with chronic constipation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The study will consist of 2-week observation and 4-week treatment periods. Patients with clinically established PD will record the status of spontaneous bowel movements and use of rescue medications\/concomitant medications in a Bowel Movement Diary from the start of the observation period at visit 1 (week \u22122). At visit 2 (week 0), patients will be assessed for final registration based on the diary records and physical examinations, and allocated to either the elobixibat or placebo group. Daily intake of the investigational drug will be recorded in the diary. Patients will undergo laboratory tests and answer constipation-related, PD-related and QOL-related questionnaires at visits 2 and 4 (week 4). Subjective symptoms and objective findings will be collected at visits 2, 3 (week 2) and 4. Since patients\u2019 motor function might be improved by treatment of constipation, the use of dopamine preparations will also be monitored. Bowel movement data and other parameters will be compared between groups.<\/jats:p>\n                    <jats:p>Safety information will be collected as adverse events, specifically focusing on those occurring in association with study conduct.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study will be conducted in accordance with the Helsinki Declaration, the Clinical Trials Act of the Japan Ministry of Health, Labour and Welfare, and related laws and regulations. The study was approved by the Juntendo University Certified Review Board. The results will be disseminated through an online study registry (Japan Registry of Clinical Trials), presented at scientific conferences, and published in medical journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>JPRN-jRCTs031200172; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-054129","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T11:36:34Z","timestamp":1644579394000},"page":"e054129","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson\u2019s disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group study (CONST-PD)"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0444","authenticated-orcid":false,"given":"Taku","family":"Hatano","sequence":"first","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-5367","authenticated-orcid":false,"given":"Genko","family":"Oyama","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1712-0845","authenticated-orcid":false,"given":"Yasushi","family":"Shimo","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Ogaki","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Urayasu Hospital, Urayasu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Fukae","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryota","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Urayasu Hospital, Urayasu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohide","family":"Kurita","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Urayasu Hospital, Urayasu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Tsunemi","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Oji","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Saiki","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Nishioka","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Takeshige-Amano","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7335-0672","authenticated-orcid":false,"given":"Takashi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikaru","family":"Kamo","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhito","family":"Fuse","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asuka","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Kano","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Nerima Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Urayasu Hospital, Urayasu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotake","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Juntendo Clinical Research and Trial Center, Juntendo University Hospital, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobutaka","family":"Hattori","sequence":"additional","affiliation":[{"name":"Neurology, Juntendo Univerity Faculty of Medicine, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"2025121403123625000_12.2.e054129.1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"2025121403123625000_12.2.e054129.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00007-1"},{"key":"2025121403123625000_12.2.e054129.3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson\u2019s disease","volume":"2","author":"Pfeiffer","year":"2003","journal-title":"The Lancet Neurology"},{"key":"2025121403123625000_12.2.e054129.4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41598-017-16790-8","article-title":"Parkinson disease with constipation: clinical features and relevant factors","volume":"8","author":"Yu","year":"2018","journal-title":"Sci Rep"},{"key":"2025121403123625000_12.2.e054129.5","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1111\/ene.13082","article-title":"Constipation: an emerging risk factor for Parkinson\u2019s disease?","volume":"23","author":"Stirpe","year":"2016","journal-title":"Eur J Neurol"},{"key":"2025121403123625000_12.2.e054129.6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3233\/JPD-160982","article-title":"The prevalence of constipation and irritable bowel syndrome in Parkinson\u2019s disease patients according to Rome III diagnostic criteria","volume":"7","author":"Mishima","year":"2017","journal-title":"J Parkinsons Dis"},{"key":"2025121403123625000_12.2.e054129.7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23884"},{"key":"2025121403123625000_12.2.e054129.8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14656566.2015.997211","article-title":"Management of constipation in Parkinson\u2019s disease","volume":"16","author":"Rossi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2025121403123625000_12.2.e054129.9","unstructured":"The Japanese Society of Gastroenterology . Clinical practice guidelines for chronic constipation ED. by Study group of the diagnosis and treatment of chronic constipation. Tokyo Japan: Nankodo Co, Ltd, 2017."},{"key":"2025121403123625000_12.2.e054129.10","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21243"},{"key":"2025121403123625000_12.2.e054129.11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182574f28"},{"key":"2025121403123625000_12.2.e054129.12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/WNL.0000000000003127","article-title":"Probiotics and prebiotic fiber for constipation associated with Parkinson disease","volume":"87","author":"Barichella","year":"2016","journal-title":"Neurology"},{"key":"2025121403123625000_12.2.e054129.13","first-page":"117","article-title":"Use of probiotics for the treatment of constipation in Parkinson\u2019s disease patients","volume":"57","author":"Cassani","year":"2011","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2025121403123625000_12.2.e054129.14","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X14528269"},{"key":"2025121403123625000_12.2.e054129.15","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.12370"},{"key":"2025121403123625000_12.2.e054129.16","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13448","article-title":"Elobixibat, an ileal bile acid transporter inhibitor, induces giant migrating contractions during natural defecation in conscious dogs","volume":"30","author":"Taniguchi","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"2025121403123625000_12.2.e054129.17","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S2468-1253(18)30123-7","article-title":"Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial","volume":"3","author":"Nakajima","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121403123625000_12.2.e054129.18","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/cs0450593","article-title":"Relationships between ion and water movement in the human jejunum, ileum and colon during perfusion with bile acids","volume":"45","author":"Wingate","year":"1973","journal-title":"Clin Sci"},{"key":"2025121403123625000_12.2.e054129.19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00194.2001"},{"key":"2025121403123625000_12.2.e054129.20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.6.818"},{"key":"2025121403123625000_12.2.e054129.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-013-0825-y"},{"key":"2025121403123625000_12.2.e054129.22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2025121403123625000_12.2.e054129.23","doi-asserted-by":"publisher","DOI":"10.1007\/BF02260863"},{"key":"2025121403123625000_12.2.e054129.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025121403123625000_12.2.e054129.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0231-6"},{"key":"2025121403123625000_12.2.e054129.26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"2025121403123625000_12.2.e054129.27","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20213"},{"key":"2025121403123625000_12.2.e054129.28","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.035"},{"key":"2025121403123625000_12.2.e054129.29","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"2025121403123625000_12.2.e054129.30","doi-asserted-by":"publisher","DOI":"10.1053\/apnr.2000.9231"},{"key":"2025121403123625000_12.2.e054129.31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00535-017-1383-5","article-title":"Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial","volume":"53","author":"Nakajima","year":"2018","journal-title":"J Gastroenterol"},{"key":"2025121403123625000_12.2.e054129.32","unstructured":"Common Technical Document section 1.5 for Goofice 5 mg tablets by EA Pharma Co., Ltd. (in Japanese), 2020. Available: https:\/\/www.pmda.go.jp\/drugs\/2018\/P20180201001\/index.html"},{"key":"2025121403123625000_12.2.e054129.33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"The Lancet"},{"key":"2025121403123625000_12.2.e054129.34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41531-020-00145-8","article-title":"Irritable bowel syndrome and Parkinson\u2019s disease risk: register-based studies","volume":"7","author":"Liu","year":"2021","journal-title":"npj Parkinsons Dis."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-054129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T11:12:44Z","timestamp":1765710764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-054129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,11]]},"published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1136\/bmjopen-2021-054129"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-054129","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}